Clinical trials: Moderate Plaque Psoriasis
Moderate-to-severe Plaque Psoriasis
Secukinumab Drug Survival, Effectiveness and Tolerability in Pediatric Patients With Psoriasis
Multicenter, non-interventional, cohort study in pediatric patients with moderate to severe plaque-type psoriasis. Retrospective data collection is planned at patients' inclusion.
- Trial name
- SPARROW (NCT06142357)
- Testing
- Secukinumab
- Where
- 16 sites in Russia
- Volunteers
- 199 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
A Study to Evaluate Efficacy and Safety of IBI112 in Adolescent Participants With Moderate to Severe Plaque Psoriasis
The purpose of this study is to evaluate the efficacy and safety of IBI112 in the treatment of adolescent participants with moderate to severe plaque-type psoriasis.
- Trial name
- NCT07265284
- Testing
- IBI112
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Plaque Psoriasis
A Randomized Double Blind Vehicle Controlled Dose Ranging Parallel Design Multiple Site Clinical Study
The objectives of this study are to evaluate the therapeutic efficacy and safety of DSXS and a Placebo in patients with moderate to severe scalp psoriasis.
- Trial name
- NCT02413229
- Testing
- DSXS1411
- Volunteers
- 151 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Psoriasis Vulgaris
Long Term Safety and Efficacy Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis
The objective of this study is to evaluate the safety and efficacy of up to 26 weeks of treatment with calcitriol 3 mcg/g ointment when used twice daily, without occlusion, to treat pediatric subjects (2 to 16 years and 11 months…
- Trial name
- NCT02125279
- Testing
- Calcitriol
- Where
- 16 sites in United States, Belgium and 3 more
- Volunteers
- 54 people
- Sponsor
- Galderma R&D
Psoriasis
A Study of the Safety and Efficacy of Ustekinumab in Adolescent Patients With Psoriasis (CADMUS)
This is a study of the safety and efficacy of ustekinumab (CNTO 1275) in adolescent patients with moderate to severe psoriasis.
- Trial name
- NCT01090427
- Testing
- Ustekinumab - Half-Standard Dosage, Ustekinumab - Standard Dosage
- Where
- 50 sites in Belgium, Canada and 8 more
- Volunteers
- 110 people
- Sponsor
- Janssen Research & Development, LLC
Plaque Psoriasis
A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis
The purpose of this study is see how effective is JNJ-77242113 in participants with moderate to severe plaque psoriasis.
- Trial name
- ICONIC-LEAD (NCT06095115)
- Testing
- JNJ-77242113
- Where
- 170 sites in United States, Argentina and 14 more
- Volunteers
- 684 people
- Sponsor
- Janssen Research & Development, LLC